New developments in flavivirus vaccines with special attention to yellow fever.

Authors:
Address: Acambis Inc., 38 Sidney Street, Cambridge, MA 02139, USA.
Journal:

Publication:

abstract

PURPOSE OF REVIEW:

Here we review recent epidemiological trends in flavivirus diseases, findings related to existing vaccines, and New directions in flavivirus vaccine research. We emphasize the need for stepped-up efforts to stop further spread and intensification of these infections worldwide.

RECENT FINDINGS:

Although the incidence and geographic distribution of flavivirus diseases have increased in recent years, human vaccines are available only for yellow fever, Japanese encephalitis, tick-borne encephalitis and Kyasanur forest disease. Factors contributing to resurgence include insufficient supplies of available vaccines, incomplete vaccination coverage and relaxation in vector control. Research has been underway for 60 years to develop effective vaccines against dengue, and recent progress is encouraging. The development of vaccines against West Nile, virus recently introduced to North America, has been initiated. In addition, there is considerable interest in improving existing vaccines with respect to increasing safety (e.g. eliminating the newly recognized syndrome of yellow fever vaccine-associated viscerotropic adverse disease), and to reducing the cost and number of doses required for effective immunization.

SUMMARY:

Traditional approaches to flavivirus vaccines are still employed, while recent advancements in biotechnology produced new approaches to vaccine design, such as recombinant live virus, subunit and DNA vaccines. Live chimeric vaccines against dengue, Japanese encephalitis and West Nile based on yellow fever 17D virus (ChimeriVax) are in phase I/II trials, with encouraging results. Other chimeric dengue, tick-borne encephalitis and West Nile virus candidates were developed based on attenuated dengue backbones. To further reduce the impact of flavivirus diseases, vaccination policies and vector control programs in affected countries require revision.

Related Articles
Review Current status of flavivirus vaccines.
Ann N Y Acad Sci. 2001
Review Current status of flavivirus vaccines.
Barrett AD. Ann N Y Acad Sci. 2001 Dec; 951:262-71.
Review Traditional and novel approaches to flavivirus vaccines.
Int J Parasitol. 2003
Review Traditional and novel approaches to flavivirus vaccines.
Pugachev KV, Guirakhoo F, Trent DW, Monath TP. Int J Parasitol. 2003 May; 33(5-6):567-82.
Review Formalin-inactivated whole virus and recombinant subunit flavivirus vaccines.
Adv Virus Res. 2003
Review Formalin-inactivated whole virus and recombinant subunit flavivirus vaccines.
Eckels KH, Putnak R. Adv Virus Res. 2003; 61:395-418.
Safety testing for neurovirulence of novel live, attenuated flavivirus vaccines: infant mice provide an accurate surrogate for the test in monkeys.
Biologicals. 2005
Safety testing for neurovirulence of novel live, attenuated flavivirus vaccines: infant mice provide an accurate surrogate for the test in monkeys.
Monath TP, Myers GA, Beck RA, Knauber M, Scappaticci K, Pullano T, Archambault WT, Catalan J, Miller C, Zhang ZX, et al. Biologicals. 2005 Sep; 33(3):131-44.
Review West Nile virus vaccine.
Curr Drug Targets Infect Disor...
Review West Nile virus vaccine.
Monath TP, Arroyo J, Miller C, Guirakhoo F. Curr Drug Targets Infect Disord. 2001 May; 1(1):37-50.
Description of a prospective 17DD yellow fever vaccine cohort in Recife, Brazil.
Am J Trop Med Hyg. 2011
Description of a prospective 17DD yellow fever vaccine cohort in Recife, Brazil.
de Melo AB, da Silva Mda P, Magalhães MC, Gonzales Gil LH, Freese de Carvalho EM, Braga-Neto UM, Bertani GR, Marques ET Jr, Cordeiro MT. Am J Trop Med Hyg. 2011 Oct; 85(4):739-47.
Role of innate signalling pathways in the immunogenicity of alphaviral replicon-based vaccines.
Virol J. 2011
Role of innate signalling pathways in the immunogenicity of alphaviral replicon-based vaccines.
Näslund TI, Kostic L, Nordström EK, Chen M, Liljeström P. Virol J. 2011 Jan 24; 8:36. Epub 2011 Jan 24.
The live-attenuated yellow fever vaccine 17D induces broad and potent T cell responses against several viral proteins in Indian rhesus macaques--implications for recombinant vaccine design.
Immunogenetics. 2010
The live-attenuated yellow fever vaccine 17D induces broad and potent T cell responses against several viral proteins in Indian rhesus macaques--implications for recombinant vaccine design.
Mudd PA, Piaskowski SM, Neves PC, Rudersdorf R, Kolar HL, Eernisse CM, Weisgrau KL, de Santana MG, Wilson NA, Bonaldo MC, et al. Immunogenetics. 2010 Sep; 62(9):593-600. Epub 2010 Jul 7.

To top • Home

TraveldoctorOnline 2001 • Disclaimer • webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.